Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients

Launched by THOMAS JEFFERSON UNIVERSITY · Aug 9, 2017

Keywords

ClinConnect Summary

This clinical trial is looking at how well patients with certain types of advanced cancer take their prescribed oral cancer medicines, especially in groups that might face challenges like low reading skills or limited income. The goal is to understand and improve how patients follow their medication schedules, which is very important for the treatment to work well.

Adults over 18 who have specific advanced cancers—such as breast, lung, colorectal, kidney, ovarian, blood cancers, or melanoma—and who are taking oral cancer medicines may be eligible. Participants should be able to communicate in English and have a performance status that means they can carry out daily activities with some limitations but are not severely disabled. People who are pregnant, living in nursing homes, or unable to give consent are not eligible. If you join the study, you can expect to have your medication habits monitored and supported to help improve how consistently you take your oral cancer drugs. This study is currently recruiting patients at Einstein Medical Center in Philadelphia, focusing on helping those who might have difficulties with medication adherence due to social or educational challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients on oral chemotherapeutic agents
• • Clinical diagnosis of stage IV breast cancer
• • Clinical diagnosis of stage III and IV colorectal cancer (not receiving concurrent radiation therapy)
• • Clinical diagnosis of stage IV non-small cell lung cancer
• • Clinical diagnosis of stage IV renal cell carcinoma
• • Clinical diagnosis of stage IV ovarian carcinoma
• • Clinical diagnosis of multiple myeloma
• • Clinical diagnosis of chronic myelogenous leukemia on TKI
• • Clinical diagnosis of myelodysplastic syndrome on Lenalidomide
• • Adjuvant treatment for Gastro Intestinal Stromal Tumor
• • Clinical diagnosis of chronic Lymphocytic Leukemia
• • Clinical diagnosis of metastatic Prostate cancer
• • Clinical diagnosis of hepatocellular Carcinoma
• • Clinical diagnosis of stage IV Melanoma
• • Clinical diagnosis of myelofibrosis/myeloproliferative neoplasms
• • Age \>18 years
• • ECOG Performance Status \<3
• Exclusion Criteria:
• • ECOG Performance Status of 3 and above
• • Concurrent chemo radiation
• • Non-English speaker
• • Clinical diagnosis of dementia, or otherwise unable to give informed consent.
• • History of non-compliance (defined as the history of 2 or more missed appointments in the clinic).
• • Pregnant patients
• • Nursing Home Patients
• • Incarcerated